Narcolepsy- Market Insight, Epidemiology and Market Forecast - 2028
This report can be delivered to the clients within 7-10 Business Days
DelveInsight’s ‘Narcolepsy - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Narcolepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Narcolepsy from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Narcolepsy - Disease Understanding and Treatment Algorithm
The DelveInsight Narcolepsy market report gives the thorough understanding of the Narcolepsy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Narcolepsy in the US, Europe, and Japan.
Narcolepsy Epidemiology
The Narcolepsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, narcolepsy with and without cataplexy prevalent cases, prevalent cases by manifestations, diagnosed cases, age-specific diagnosed cases) scenario of Narcolepsy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.
According to DelveInsight, total prevalent population of Narcolepsy in 7 major markets are about 507,138 in 2016.
Narcolepsy Drug Chapters
This segment of the Narcolepsy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Therapeutic market is dominated with the use of the pharmacological therapies for the treatment of the signs and symptoms such as Cataplexy, Excessive daytime sleepiness (EDS) and without Cataplexy associated with Narcolepsy. Detailed chapter for upcoming therapies BTD-001 (Balance Therapeutics), JZP-258 (Jazz Pharmaceuticals), Xyrem (Jazz Pharmaceuticals), TS-091 (Taisho Pharmaceutical Co., Ltd.), THN102 (Theranexus) and pitolisant (Bioprojet Pharma) have been covered in the report.
Narcolepsy Market Outlook
The Narcolepsy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Narcolepsy in 7MM was found to be USD 1,262 Million in 2016, and is expected to increase at a CAGR of XX% from 2016-2028.
Narcolepsy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Narcolepsy Report Insights
DelveInsight’s ‘Narcolepsy - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Narcolepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Narcolepsy from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Narcolepsy - Disease Understanding and Treatment Algorithm
The DelveInsight Narcolepsy market report gives the thorough understanding of the Narcolepsy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Narcolepsy in the US, Europe, and Japan.
Narcolepsy Epidemiology
The Narcolepsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, narcolepsy with and without cataplexy prevalent cases, prevalent cases by manifestations, diagnosed cases, age-specific diagnosed cases) scenario of Narcolepsy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.
According to DelveInsight, total prevalent population of Narcolepsy in 7 major markets are about 507,138 in 2016.
Narcolepsy Drug Chapters
This segment of the Narcolepsy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Therapeutic market is dominated with the use of the pharmacological therapies for the treatment of the signs and symptoms such as Cataplexy, Excessive daytime sleepiness (EDS) and without Cataplexy associated with Narcolepsy. Detailed chapter for upcoming therapies BTD-001 (Balance Therapeutics), JZP-258 (Jazz Pharmaceuticals), Xyrem (Jazz Pharmaceuticals), TS-091 (Taisho Pharmaceutical Co., Ltd.), THN102 (Theranexus) and pitolisant (Bioprojet Pharma) have been covered in the report.
Narcolepsy Market Outlook
The Narcolepsy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Narcolepsy in 7MM was found to be USD 1,262 Million in 2016, and is expected to increase at a CAGR of XX% from 2016-2028.
Narcolepsy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Narcolepsy Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Narcolepsy market
- Organize sales and marketing efforts by identifying the best opportunities for Narcolepsy market
- To understand the future market competition in the Narcolepsy market.
1. KEY INSIGHTS
2. NARCOLEPSY MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of Narcolepsy in 2016
2.2. Market Share (%) Distribution of Narcolepsy in 2028
3. DISEASE BACKGROUND AND OVERVIEW: NARCOLEPSY
3.1. Introduction
3.2. Signs and Symptoms
3.3. Complications
3.4. Pathophysiology
3.5. Etiology
3.6. Risk Factors
3.7. Diagnosis
3.8. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
5. 7MM TOTAL PREVALENT PATIENT POPULATION OF NARCOLEPSY
5.1. United States
5.1.1. Prevalent Patient Population of Narcolepsy in the United States
5.1.2. Narcolepsy with and without Cataplexy Cases
5.1.3. Prevalent Cases by Clinical Manifestation
5.1.4. Diagnosed Cases of Narcolepsy
5.1.5. Age-Specific Diagnosed Cases of Narcolepsy
5.2. Germany
5.2.1. Prevalent Population of Narcolepsy
5.2.2. Narcolepsy cases with and without Cataplexy
5.2.3. Prevalent Cases by Clinical Manifestation
5.2.4. Diagnosed Cases of Narcolepsy
5.2.5. Age-Specific Diagnosed Cases of Narcolepsy
5.3. France
5.3.1. Prevalent Population of Narcolepsy
5.3.2. Narcolepsy cases with and without Cataplexy
5.3.3. Prevalent Cases by Clinical Manifestation
5.3.4. Diagnosed Cases of Narcolepsy
5.3.5. Age-Specific Diagnosed Cases of Narcolepsy
5.4. Italy
5.4.1. Prevalent Population of Narcolepsy in Italy
5.4.2. Narcolepsy cases with and without Cataplexy
5.4.3. Prevalent Cases by Clinical Manifestation
5.4.4. Diagnosed Cases of Narcolepsy
5.4.5. Age-Specific Diagnosed Cases of Narcolepsy
5.5. Spain
5.5.1. Prevalent Population of Narcolepsy
5.5.2. Narcolepsy cases with and without Cataplexy
5.5.3. Prevalent Cases by Clinical Manifestation
5.5.4. Diagnosed Cases of Narcolepsy
5.5.5. Age-Specific Diagnosed Cases of Narcolepsy
5.6. United Kingdom
5.6.1. Prevalent Cases of Narcolepsy
5.6.2. Narcolepsy cases with and without Cataplexy
5.6.3. Prevalent Cases by Clinical Manifestation
5.6.4. Diagnosed Cases of Narcolepsy
5.6.5. Age-Specific Diagnosed Cases of Narcolepsy
5.7. Japan
5.8. Prevalent Population of Narcolepsy
5.9. Narcolepsy cases with and without Cataplexy
5.10. Prevalent Cases by Clinical Manifestation
5.11. Diagnosed Cases of Narcolepsy
5.12. Age-Specific Diagnosed Cases of Narcolepsy
6. CURRENT TREATMENT AND MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Guideline and management
7. UNMET NEEDS
8. MARKETED DRUGS
8.1. PROVIGIL
8.1.1. Drug Description
8.1.2. Regulatory Milestones
8.1.3. Advantages & Disadvantages
8.1.4. Product Profile
8.2. XYREM
8.2.1. Description
8.2.2. Regulatory Milestones
8.2.3. Advantages and Disadvantages
8.2.4. Product Profile
9. OTHER NARCOLEPTICS
9.1. Anafranil (clomipramine)
9.1.1. Description
9.1.2. Regulatory Milestones
9.1.3. Advantages and Disadvantages
9.1.4. Product Profile
9.2. Desipramine
9.2.1. Description
9.2.2. Regulatory Milestones
9.2.3. Advantages and Disadvantages
9.2.4. Product Profile
9.3. Prozac (Fluoxetine)
9.3.1. Description
9.3.2. Regulatory Milestones
9.3.3. Advantages and Disadvantages
9.3.4. Product Profile
9.4. Tofranil (Imipramine)
9.4.1. Description
9.4.2. Advantages and Disadvantages
9.4.3. Product Profile
9.5. Vivactil (Protriptyline)
9.5.1. Description
9.5.2. Regulatory Milestones
9.5.3. Advantages and Disadvantages
9.5.4. Product Profile
9.6. Zoloft (Sertraline)
9.6.1. Description
9.6.2. Regulatory Milestones
9.6.3. Advantages and Disadvantages
9.6.4. Product Profile
9.7. Effexor (Venlafaxine)
9.7.1. Description
9.7.2. Regulatory Milestones
9.7.3. Advantages and Disadvantages
9.7.4. Product Profile
9.8. Desoxyn (Methamphetamine)
9.8.1. Description
9.8.2. Regulatory Milestones
9.8.3. Advantages and Disadvantages
9.8.4. Product Profile
9.9. NUVIGIL
9.9.1. Description
9.9.2. Regulatory Milestones
9.9.3. Advantages and Disadvantages
9.9.4. Product Profile
9.10. Wakix (Pitolisant)
9.10.1. Description
9.10.2. Regulatory Milestones
9.10.3. Advantages and Disadvantages
9.10.4. Product Profile
9.11. Ritalin
9.11.1. Description
9.11.2. Regulatory Milestones
9.11.3. Advantages and Disadvantages
9.11.4. Product Profile
9.12. Dexedrine
9.12.1. Description
9.12.2. Regulatory Milestones
9.12.3. Advantages and Disadvantages
9.12.4. Product Profile
9.13. Adderall
9.13.1. Description
9.13.2. Regulatory Milestones
9.13.3. Advantages and Disadvantages
9.13.4. Product Profile
9.14. Atomoxetine
9.14.1. Description
9.14.2. Regulatory Milestones:
9.14.3. Advantages and Disadvantages
9.14.4. Product Profile
10. EMERGING DRUGS
10.1. Xyrem: Jazz Pharmaceuticals
10.1.1. Regulatory Milestones
10.1.2. Clinical Development
10.1.3. Clinical Trial Information
10.1.4. Product Profile
10.2. Mazindol CR: NLS Pharma
10.2.1. Product Description
10.2.2. Product Development Activities
10.2.3. Product Profile
10.3. JZP-258: Jazz Pharmaceuticals Inc
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Clinical Development
10.3.4. Product Profile
10.4. JZP-110: Jazz Pharmaceuticals
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Pre-Clinical Development
10.4.4. Clinical Development
10.4.5. Safety and Efficacy
10.4.6. Product Profile
10.5. Sodium oxybate ER: Avadel Pharmaceuticals
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Clinical Developments
10.5.4. Product Profile
10.6. TS-091: Taisho Pharmaceutical Co
10.6.1. Clinical Development
10.6.2. Clinical Trial Information
10.6.3. Product Profile
10.7. BTD – 001: Balance Therapeutics
10.7.1. Clinical Development
10.7.2. Clinical Trial Information
10.7.3. Product Profile
10.8. Pitolisant: Bioprojet
10.8.1. Regulatory Milestones
10.8.2. Other Clinical Activities
10.8.3. Clinical Development
10.8.4. Clinical Trial Information
10.8.5. Product Profile
10.9. THN102 (Modafinil + Flecainide): Theranexus
10.9.1. Regulatory Milestones
10.9.2. Clinical Development
10.9.3. Clinical Trial Information
10.9.4. Product Profile
11. NARCOLEPSY: 7 MAJOR MARKET ANALYSIS
12. NARCOLEPSY: 7 MAJOR MARKET OUTLOOK
13. MARKET SIZE OF NARCOLEPSY IN 7MM
14. MARKET OUTLOOK BY COUNTRY
14.1. The United States: Market Outlook
14.1.1. Total Market size of Narcolepsy in the U.S.
14.1.2. Therapy-based market size of Narcolepsy in the U.S.
14.2. EU-5 Countries: Market Outlook
14.2.1. Germany
14.2.2. Total Market size of Narcolepsy in Germany
14.2.3. Therapy-based market size of Narcolepsy in Germany
14.2.4. France
14.2.5. Total Market size of Narcolepsy in France
14.2.6. Therapy-based market size of Narcolepsy in France
14.2.7. United Kingdom
14.2.8. Total Market size of Narcolepsy in the UK
14.2.9. Therapy-based market size of Narcolepsy in the UK
14.2.10. Spain
14.2.11. Total Market size of Narcolepsy in Spain
14.2.12. Therapy-based market size of Narcolepsy in Spain
14.2.13. Italy
14.2.14. Total Market size of Narcolepsy in Italy
14.2.15. Therapy-based market size of Narcolepsy in Italy
14.3. Japan
14.3.1. Market Outlook
14.3.2. Total Market size of Narcolepsy in Japan
14.3.3. Therapy-based market size of Narcolepsy in Japan
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
18. REPORT METHODOLOGY
18.1. Sources Used
19. DELVEINSIGHT CAPABILITIES
20. DISCLAIMER
21. ABOUT DELVEINSIGHT
2. NARCOLEPSY MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of Narcolepsy in 2016
2.2. Market Share (%) Distribution of Narcolepsy in 2028
3. DISEASE BACKGROUND AND OVERVIEW: NARCOLEPSY
3.1. Introduction
3.2. Signs and Symptoms
3.3. Complications
3.4. Pathophysiology
3.5. Etiology
3.6. Risk Factors
3.7. Diagnosis
3.8. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
5. 7MM TOTAL PREVALENT PATIENT POPULATION OF NARCOLEPSY
5.1. United States
5.1.1. Prevalent Patient Population of Narcolepsy in the United States
5.1.2. Narcolepsy with and without Cataplexy Cases
5.1.3. Prevalent Cases by Clinical Manifestation
5.1.4. Diagnosed Cases of Narcolepsy
5.1.5. Age-Specific Diagnosed Cases of Narcolepsy
5.2. Germany
5.2.1. Prevalent Population of Narcolepsy
5.2.2. Narcolepsy cases with and without Cataplexy
5.2.3. Prevalent Cases by Clinical Manifestation
5.2.4. Diagnosed Cases of Narcolepsy
5.2.5. Age-Specific Diagnosed Cases of Narcolepsy
5.3. France
5.3.1. Prevalent Population of Narcolepsy
5.3.2. Narcolepsy cases with and without Cataplexy
5.3.3. Prevalent Cases by Clinical Manifestation
5.3.4. Diagnosed Cases of Narcolepsy
5.3.5. Age-Specific Diagnosed Cases of Narcolepsy
5.4. Italy
5.4.1. Prevalent Population of Narcolepsy in Italy
5.4.2. Narcolepsy cases with and without Cataplexy
5.4.3. Prevalent Cases by Clinical Manifestation
5.4.4. Diagnosed Cases of Narcolepsy
5.4.5. Age-Specific Diagnosed Cases of Narcolepsy
5.5. Spain
5.5.1. Prevalent Population of Narcolepsy
5.5.2. Narcolepsy cases with and without Cataplexy
5.5.3. Prevalent Cases by Clinical Manifestation
5.5.4. Diagnosed Cases of Narcolepsy
5.5.5. Age-Specific Diagnosed Cases of Narcolepsy
5.6. United Kingdom
5.6.1. Prevalent Cases of Narcolepsy
5.6.2. Narcolepsy cases with and without Cataplexy
5.6.3. Prevalent Cases by Clinical Manifestation
5.6.4. Diagnosed Cases of Narcolepsy
5.6.5. Age-Specific Diagnosed Cases of Narcolepsy
5.7. Japan
5.8. Prevalent Population of Narcolepsy
5.9. Narcolepsy cases with and without Cataplexy
5.10. Prevalent Cases by Clinical Manifestation
5.11. Diagnosed Cases of Narcolepsy
5.12. Age-Specific Diagnosed Cases of Narcolepsy
6. CURRENT TREATMENT AND MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Guideline and management
7. UNMET NEEDS
8. MARKETED DRUGS
8.1. PROVIGIL
8.1.1. Drug Description
8.1.2. Regulatory Milestones
8.1.3. Advantages & Disadvantages
8.1.4. Product Profile
8.2. XYREM
8.2.1. Description
8.2.2. Regulatory Milestones
8.2.3. Advantages and Disadvantages
8.2.4. Product Profile
9. OTHER NARCOLEPTICS
9.1. Anafranil (clomipramine)
9.1.1. Description
9.1.2. Regulatory Milestones
9.1.3. Advantages and Disadvantages
9.1.4. Product Profile
9.2. Desipramine
9.2.1. Description
9.2.2. Regulatory Milestones
9.2.3. Advantages and Disadvantages
9.2.4. Product Profile
9.3. Prozac (Fluoxetine)
9.3.1. Description
9.3.2. Regulatory Milestones
9.3.3. Advantages and Disadvantages
9.3.4. Product Profile
9.4. Tofranil (Imipramine)
9.4.1. Description
9.4.2. Advantages and Disadvantages
9.4.3. Product Profile
9.5. Vivactil (Protriptyline)
9.5.1. Description
9.5.2. Regulatory Milestones
9.5.3. Advantages and Disadvantages
9.5.4. Product Profile
9.6. Zoloft (Sertraline)
9.6.1. Description
9.6.2. Regulatory Milestones
9.6.3. Advantages and Disadvantages
9.6.4. Product Profile
9.7. Effexor (Venlafaxine)
9.7.1. Description
9.7.2. Regulatory Milestones
9.7.3. Advantages and Disadvantages
9.7.4. Product Profile
9.8. Desoxyn (Methamphetamine)
9.8.1. Description
9.8.2. Regulatory Milestones
9.8.3. Advantages and Disadvantages
9.8.4. Product Profile
9.9. NUVIGIL
9.9.1. Description
9.9.2. Regulatory Milestones
9.9.3. Advantages and Disadvantages
9.9.4. Product Profile
9.10. Wakix (Pitolisant)
9.10.1. Description
9.10.2. Regulatory Milestones
9.10.3. Advantages and Disadvantages
9.10.4. Product Profile
9.11. Ritalin
9.11.1. Description
9.11.2. Regulatory Milestones
9.11.3. Advantages and Disadvantages
9.11.4. Product Profile
9.12. Dexedrine
9.12.1. Description
9.12.2. Regulatory Milestones
9.12.3. Advantages and Disadvantages
9.12.4. Product Profile
9.13. Adderall
9.13.1. Description
9.13.2. Regulatory Milestones
9.13.3. Advantages and Disadvantages
9.13.4. Product Profile
9.14. Atomoxetine
9.14.1. Description
9.14.2. Regulatory Milestones:
9.14.3. Advantages and Disadvantages
9.14.4. Product Profile
10. EMERGING DRUGS
10.1. Xyrem: Jazz Pharmaceuticals
10.1.1. Regulatory Milestones
10.1.2. Clinical Development
10.1.3. Clinical Trial Information
10.1.4. Product Profile
10.2. Mazindol CR: NLS Pharma
10.2.1. Product Description
10.2.2. Product Development Activities
10.2.3. Product Profile
10.3. JZP-258: Jazz Pharmaceuticals Inc
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Clinical Development
10.3.4. Product Profile
10.4. JZP-110: Jazz Pharmaceuticals
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Pre-Clinical Development
10.4.4. Clinical Development
10.4.5. Safety and Efficacy
10.4.6. Product Profile
10.5. Sodium oxybate ER: Avadel Pharmaceuticals
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Clinical Developments
10.5.4. Product Profile
10.6. TS-091: Taisho Pharmaceutical Co
10.6.1. Clinical Development
10.6.2. Clinical Trial Information
10.6.3. Product Profile
10.7. BTD – 001: Balance Therapeutics
10.7.1. Clinical Development
10.7.2. Clinical Trial Information
10.7.3. Product Profile
10.8. Pitolisant: Bioprojet
10.8.1. Regulatory Milestones
10.8.2. Other Clinical Activities
10.8.3. Clinical Development
10.8.4. Clinical Trial Information
10.8.5. Product Profile
10.9. THN102 (Modafinil + Flecainide): Theranexus
10.9.1. Regulatory Milestones
10.9.2. Clinical Development
10.9.3. Clinical Trial Information
10.9.4. Product Profile
11. NARCOLEPSY: 7 MAJOR MARKET ANALYSIS
12. NARCOLEPSY: 7 MAJOR MARKET OUTLOOK
13. MARKET SIZE OF NARCOLEPSY IN 7MM
14. MARKET OUTLOOK BY COUNTRY
14.1. The United States: Market Outlook
14.1.1. Total Market size of Narcolepsy in the U.S.
14.1.2. Therapy-based market size of Narcolepsy in the U.S.
14.2. EU-5 Countries: Market Outlook
14.2.1. Germany
14.2.2. Total Market size of Narcolepsy in Germany
14.2.3. Therapy-based market size of Narcolepsy in Germany
14.2.4. France
14.2.5. Total Market size of Narcolepsy in France
14.2.6. Therapy-based market size of Narcolepsy in France
14.2.7. United Kingdom
14.2.8. Total Market size of Narcolepsy in the UK
14.2.9. Therapy-based market size of Narcolepsy in the UK
14.2.10. Spain
14.2.11. Total Market size of Narcolepsy in Spain
14.2.12. Therapy-based market size of Narcolepsy in Spain
14.2.13. Italy
14.2.14. Total Market size of Narcolepsy in Italy
14.2.15. Therapy-based market size of Narcolepsy in Italy
14.3. Japan
14.3.1. Market Outlook
14.3.2. Total Market size of Narcolepsy in Japan
14.3.3. Therapy-based market size of Narcolepsy in Japan
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
18. REPORT METHODOLOGY
18.1. Sources Used
19. DELVEINSIGHT CAPABILITIES
20. DISCLAIMER
21. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Total Prevalent Patient Population of Narcolepsy in the 7MM (2016-2028)
Table 2: Prevalent Cases of Narcolepsy in the United States (2016-2028)
Table 3: Narcolepsy with and without Cataplexy Cases in the United States (2016-2028)
Table 4: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United States (2016-2028)
Table 5: Diagnosed Cases of Narcolepsy in the United States (2016-2028)
Table 6: Age-Specific Diagnosed Cases of Narcolepsy in United States (2016-2028)
Table 7: Prevalent Cases of Narcolepsy in Germany (2016-2028)
Table 8: Narcolepsy with and without Cataplexy Cases in Germany (2016-2028)
Table 9: Prevalent Cases of Narcolepsy by Clinical Manifestations in Germany (2016-2028)
Table 10: Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Table 11: Age-Specific Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Table 12: Prevalent Cases of Narcolepsy in France (2016-2028)
Table 13: Narcolepsy with and without Cataplexy cases in France (2016-2028)
Table 14: Prevalent Cases of Narcolepsy by Clinical Manifestations in France (2016-2028)
Table 15: Diagnosed Cases of Narcolepsy in France (2063-2027)
Table 16: Age-Specific Diagnosed Cases of Narcolepsy in France (2016-2028)
Table 17: Prevalent Population of Narcolepsy in Italy (2016-2028)
Table 18: Narcolepsy with and without Cataplexy cases in Italy (2016-2028)
Table 19: Prevalent Cases of Narcolepsy by Clinical Manifestations in Italy (2016-2028)
Table 20: Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Table 21: Age-Specific Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Table 22: Prevalent Cases of Narcolepsy in Spain (2016-2028)
Table 23: Narcolepsy with and without Cataplexy Cases in Spain (2016-2028)
Table 24: Prevalent Cases of Narcolepsy by Clinical Manifestations in Spain (2016-2028)
Table 25: Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Table 26: Age-Specific Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Table 27: Prevalent Cases of Narcolepsy in the United Kingdom (2016-2028)
Table 28: Narcolepsy with and without Cataplexy cases in the United Kingdom (2016-2028)
Table 29: Prevalent Cases of Narcolepsy by Clinical Manifestations in United Kingdom (2016-2028)
Table 30: Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Table 31: Age-Specific Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Table 32: Prevalent Cases of Narcolepsy in Japan (2016-2028)
Table 33: Narcolepsy with and without Cataplexy cases in Japan (2016-2028)
Table 34: Prevalent Cases of Narcolepsy by Clinical Manifestations in Japan (2016-2028)
Table 35: Diagnosed Cases of Narcolepsy in Japan (2016-2028)
Table 36: Age-Specific Diagnosed Cases of Narcolepsy in Japan (2016-2028)
Table 37: THN102 Clinical Trial Description
Table 38: JZP-110, Clinical Trial Description
Table 39: Sodium oxybate, Clinical Trial Description
Table 40: TS-091 Clinical Trial Description
Table 41: BTD-001 Clinical Trial Description
Table 42: Pitolisant Clinical Trial Description
Table 43: THN102 Clinical Trial Description
Table 44: 7 Major Market Size of Narcolepsy in USD Million (2016-2028)
Table 45: Market Size of Narcolepsy in the United States, USD Million (2016-2028)
Table 46: Therapy-based Market Size of Narcolepsy in the US, in USD Million (2016-2028))
Table 47: Market Size of Narcolepsy in Germany, in USD Million (2016-2028)
Table 48: Therapy-based Market Size of Narcolepsy in Germany, in USD Million (2016-2028))
Table 49: Market Size of Narcolepsy in France, in USD Million (2016-2028)
Table 50: Therapy-based Market Size of Narcolepsy in France, in USD Million (2016-2028)
Table 51: Market Size of Narcolepsy in the UK, in USD Million (2016-2028)
Table 52: Therapy-based Market Size of Narcolepsy in the UK, in USD Million (2016-2028))
Table 53: Market Size of Narcolepsy in Spain, in USD Million (2016-2028)
Table 54: Therapy-based Market Size of Narcolepsy in Spain, in USD Million (2016-2028))
Table 55: Market Size of Narcolepsy in Italy, in USD Million (2016-2028)
Table 56: Therapy-based Market Size of Narcolepsy in Italy, in USD Million (2016-2028))
Table 57: Market Size of Narcolepsy in Japan, in USD Million (2016-2028)
Table 58: Therapy-based Market Size of Narcolepsy in in Japan, in USD Million (2016-2028)
Table 1: Total Prevalent Patient Population of Narcolepsy in the 7MM (2016-2028)
Table 2: Prevalent Cases of Narcolepsy in the United States (2016-2028)
Table 3: Narcolepsy with and without Cataplexy Cases in the United States (2016-2028)
Table 4: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United States (2016-2028)
Table 5: Diagnosed Cases of Narcolepsy in the United States (2016-2028)
Table 6: Age-Specific Diagnosed Cases of Narcolepsy in United States (2016-2028)
Table 7: Prevalent Cases of Narcolepsy in Germany (2016-2028)
Table 8: Narcolepsy with and without Cataplexy Cases in Germany (2016-2028)
Table 9: Prevalent Cases of Narcolepsy by Clinical Manifestations in Germany (2016-2028)
Table 10: Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Table 11: Age-Specific Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Table 12: Prevalent Cases of Narcolepsy in France (2016-2028)
Table 13: Narcolepsy with and without Cataplexy cases in France (2016-2028)
Table 14: Prevalent Cases of Narcolepsy by Clinical Manifestations in France (2016-2028)
Table 15: Diagnosed Cases of Narcolepsy in France (2063-2027)
Table 16: Age-Specific Diagnosed Cases of Narcolepsy in France (2016-2028)
Table 17: Prevalent Population of Narcolepsy in Italy (2016-2028)
Table 18: Narcolepsy with and without Cataplexy cases in Italy (2016-2028)
Table 19: Prevalent Cases of Narcolepsy by Clinical Manifestations in Italy (2016-2028)
Table 20: Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Table 21: Age-Specific Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Table 22: Prevalent Cases of Narcolepsy in Spain (2016-2028)
Table 23: Narcolepsy with and without Cataplexy Cases in Spain (2016-2028)
Table 24: Prevalent Cases of Narcolepsy by Clinical Manifestations in Spain (2016-2028)
Table 25: Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Table 26: Age-Specific Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Table 27: Prevalent Cases of Narcolepsy in the United Kingdom (2016-2028)
Table 28: Narcolepsy with and without Cataplexy cases in the United Kingdom (2016-2028)
Table 29: Prevalent Cases of Narcolepsy by Clinical Manifestations in United Kingdom (2016-2028)
Table 30: Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Table 31: Age-Specific Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Table 32: Prevalent Cases of Narcolepsy in Japan (2016-2028)
Table 33: Narcolepsy with and without Cataplexy cases in Japan (2016-2028)
Table 34: Prevalent Cases of Narcolepsy by Clinical Manifestations in Japan (2016-2028)
Table 35: Diagnosed Cases of Narcolepsy in Japan (2016-2028)
Table 36: Age-Specific Diagnosed Cases of Narcolepsy in Japan (2016-2028)
Table 37: THN102 Clinical Trial Description
Table 38: JZP-110, Clinical Trial Description
Table 39: Sodium oxybate, Clinical Trial Description
Table 40: TS-091 Clinical Trial Description
Table 41: BTD-001 Clinical Trial Description
Table 42: Pitolisant Clinical Trial Description
Table 43: THN102 Clinical Trial Description
Table 44: 7 Major Market Size of Narcolepsy in USD Million (2016-2028)
Table 45: Market Size of Narcolepsy in the United States, USD Million (2016-2028)
Table 46: Therapy-based Market Size of Narcolepsy in the US, in USD Million (2016-2028))
Table 47: Market Size of Narcolepsy in Germany, in USD Million (2016-2028)
Table 48: Therapy-based Market Size of Narcolepsy in Germany, in USD Million (2016-2028))
Table 49: Market Size of Narcolepsy in France, in USD Million (2016-2028)
Table 50: Therapy-based Market Size of Narcolepsy in France, in USD Million (2016-2028)
Table 51: Market Size of Narcolepsy in the UK, in USD Million (2016-2028)
Table 52: Therapy-based Market Size of Narcolepsy in the UK, in USD Million (2016-2028))
Table 53: Market Size of Narcolepsy in Spain, in USD Million (2016-2028)
Table 54: Therapy-based Market Size of Narcolepsy in Spain, in USD Million (2016-2028))
Table 55: Market Size of Narcolepsy in Italy, in USD Million (2016-2028)
Table 56: Therapy-based Market Size of Narcolepsy in Italy, in USD Million (2016-2028))
Table 57: Market Size of Narcolepsy in Japan, in USD Million (2016-2028)
Table 58: Therapy-based Market Size of Narcolepsy in in Japan, in USD Million (2016-2028)
LIST OF FIGURES
Figure 1: Complications of Narcolepsy
Figure 2: Pathophysiology of Narcolepsy
Figure 3: Prevalent Cases of Narcolepsy in the United States (2016-2028)
Figure 4: Narcolepsy with and without Cataplexy Cases in the United States (2016-2028)
Figure 5: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United States (2016-2028)
Figure 6: Diagnosed Cases of Narcolepsy in the United States (2016-2028)
Figure 7: Age-Specific Diagnosed Cases of Narcolepsy in the United States (2016-2028)
Figure 8:Prevalent Cases of Narcolepsy in Germany (2016-2028)
Figure 9: Narcolepsy with and without Cataplexy Cases in Germany (2016-2028)
Figure 10: Prevalent Cases of Narcolepsy by Clinical Manifestations in Germany (2016-2028)
Figure 11: Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Figure 12: Age-Specific Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Figure 13: Prevalent Cases of Narcolepsy in France (2016-2028)
Figure 14: Narcolepsy with and without Cataplexy cases in France (2016-2028)
Figure 15: Prevalent Cases of Narcolepsy by Clinical Manifestations in France (2016-2028)
Figure 16: Diagnosed Cases of Narcolepsy in France (2016-2028)
Figure 17: Age-Specific Diagnosed Cases of Narcolepsy in France (2016-2028)
Figure 18: Prevalent Population of Narcolepsy in Italy (2016-2028)
Figure 19: Narcolepsy with and without Cataplexy cases in Italy (2016-2028)
Figure 20: Prevalent Cases of Narcolepsy by Clinical Manifestations in Italy (2016-2028)
Figure 21: Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Figure 22: Age-Specific Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Figure 23: Prevalent Cases of Narcolepsy in Spain (2016-2028)
Figure 24: Narcolepsy with and without Cataplexy Cases in Spain (2016-2028)
Figure 25: Prevalent Cases of Narcolepsy by Clinical Manifestations in Spain (2016-2028)
Figure 26: Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Figure 27: Age-Specific Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Figure 28: Prevalent Cases of Narcolepsy in the United Kingdom (2016-2028)
Figure 29: Narcolepsy with and without Cataplexy cases in the United Kingdom (2016-2028)
Figure 30: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United Kingdom (2016-2028)
Figure 31: Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Figure 32: Age-Specific Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Figure 33: Prevalent Population of Narcolepsy in Japan (2016-2028)
Figure 34: Narcolepsy with and without Cataplexy cases in Japan (2016-2028)
Figure 35: Prevalent Cases of Narcolepsy by Clinical Manifestations in Japan (2016-2028)
Figure 36: Total Prevalent Population of Narcolepsy in Japan (2016-2028)
Figure 37: Age-Specific Diagnosed Cases of Narcolepsy in Japan (2016-2028)
Figure 38: Treatment Practices of Narcolepsy
Table 39: Therapies for the treatment of Excessive daytime sleepiness and irresistible episodes of sleep with Narcolepsy
Figure 40: Unmet Needs of Narcolepsy
Figure 41: 7 Major Market Size of Narcolepsy in USD Million (2016-2028)
Figure 42: Market Size of Narcolepsy in the US, in USD Million (2016-2028)
Figure 43: Therapy-based Market Size of Narcolepsy in the US, in USD Million (2016-2028)
Figure 44: Market Size of Narcolepsy in Germany, USD Millions (2016-2028)
Figure 45: Therapy-based Market Size of Narcolepsy in Germany, in USD Million (2016-2028)
Figure 46: Market Size of Narcolepsy in France, in USD Million (2016-2028)
Figure 47: Therapy-based Market Size of Narcolepsy in France, in USD Million (2016-2028)
Figure 48: Market Size of Narcolepsy in the UK, USD Millions (2016-2028)
Figure 49: Therapy-based Market Size of Narcolepsy in the UK, in USD Million (2016-2028)
Figure 50: Market Size of Narcolepsy in Spain, in USD Million (2016-2028)
Figure 51: Therapy-based Market Size of Narcolepsy in Spain, in USD Million (2016-2028)
Figure 52: Market Size of Narcolepsy in Italy, in USD Million (2016-2028)
Figure 53: Therapy-based Market Size of Narcolepsy in Italy, in USD Million (2016-2028)
Figure 54: Market Size of Narcolepsy in Japan, in USD Million (2016-2028)
Figure 55: Therapy-based Market Size of Narcolepsy in Japan, in USD Million (2016-2028)
Figure 56: Market Drivers
Figure 57:Market Barriers
Figure 1: Complications of Narcolepsy
Figure 2: Pathophysiology of Narcolepsy
Figure 3: Prevalent Cases of Narcolepsy in the United States (2016-2028)
Figure 4: Narcolepsy with and without Cataplexy Cases in the United States (2016-2028)
Figure 5: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United States (2016-2028)
Figure 6: Diagnosed Cases of Narcolepsy in the United States (2016-2028)
Figure 7: Age-Specific Diagnosed Cases of Narcolepsy in the United States (2016-2028)
Figure 8:Prevalent Cases of Narcolepsy in Germany (2016-2028)
Figure 9: Narcolepsy with and without Cataplexy Cases in Germany (2016-2028)
Figure 10: Prevalent Cases of Narcolepsy by Clinical Manifestations in Germany (2016-2028)
Figure 11: Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Figure 12: Age-Specific Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Figure 13: Prevalent Cases of Narcolepsy in France (2016-2028)
Figure 14: Narcolepsy with and without Cataplexy cases in France (2016-2028)
Figure 15: Prevalent Cases of Narcolepsy by Clinical Manifestations in France (2016-2028)
Figure 16: Diagnosed Cases of Narcolepsy in France (2016-2028)
Figure 17: Age-Specific Diagnosed Cases of Narcolepsy in France (2016-2028)
Figure 18: Prevalent Population of Narcolepsy in Italy (2016-2028)
Figure 19: Narcolepsy with and without Cataplexy cases in Italy (2016-2028)
Figure 20: Prevalent Cases of Narcolepsy by Clinical Manifestations in Italy (2016-2028)
Figure 21: Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Figure 22: Age-Specific Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Figure 23: Prevalent Cases of Narcolepsy in Spain (2016-2028)
Figure 24: Narcolepsy with and without Cataplexy Cases in Spain (2016-2028)
Figure 25: Prevalent Cases of Narcolepsy by Clinical Manifestations in Spain (2016-2028)
Figure 26: Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Figure 27: Age-Specific Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Figure 28: Prevalent Cases of Narcolepsy in the United Kingdom (2016-2028)
Figure 29: Narcolepsy with and without Cataplexy cases in the United Kingdom (2016-2028)
Figure 30: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United Kingdom (2016-2028)
Figure 31: Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Figure 32: Age-Specific Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Figure 33: Prevalent Population of Narcolepsy in Japan (2016-2028)
Figure 34: Narcolepsy with and without Cataplexy cases in Japan (2016-2028)
Figure 35: Prevalent Cases of Narcolepsy by Clinical Manifestations in Japan (2016-2028)
Figure 36: Total Prevalent Population of Narcolepsy in Japan (2016-2028)
Figure 37: Age-Specific Diagnosed Cases of Narcolepsy in Japan (2016-2028)
Figure 38: Treatment Practices of Narcolepsy
Table 39: Therapies for the treatment of Excessive daytime sleepiness and irresistible episodes of sleep with Narcolepsy
Figure 40: Unmet Needs of Narcolepsy
Figure 41: 7 Major Market Size of Narcolepsy in USD Million (2016-2028)
Figure 42: Market Size of Narcolepsy in the US, in USD Million (2016-2028)
Figure 43: Therapy-based Market Size of Narcolepsy in the US, in USD Million (2016-2028)
Figure 44: Market Size of Narcolepsy in Germany, USD Millions (2016-2028)
Figure 45: Therapy-based Market Size of Narcolepsy in Germany, in USD Million (2016-2028)
Figure 46: Market Size of Narcolepsy in France, in USD Million (2016-2028)
Figure 47: Therapy-based Market Size of Narcolepsy in France, in USD Million (2016-2028)
Figure 48: Market Size of Narcolepsy in the UK, USD Millions (2016-2028)
Figure 49: Therapy-based Market Size of Narcolepsy in the UK, in USD Million (2016-2028)
Figure 50: Market Size of Narcolepsy in Spain, in USD Million (2016-2028)
Figure 51: Therapy-based Market Size of Narcolepsy in Spain, in USD Million (2016-2028)
Figure 52: Market Size of Narcolepsy in Italy, in USD Million (2016-2028)
Figure 53: Therapy-based Market Size of Narcolepsy in Italy, in USD Million (2016-2028)
Figure 54: Market Size of Narcolepsy in Japan, in USD Million (2016-2028)
Figure 55: Therapy-based Market Size of Narcolepsy in Japan, in USD Million (2016-2028)
Figure 56: Market Drivers
Figure 57:Market Barriers
